Finerenone Plus Empagliflozin Decrease UACR in CKD Patients With T2D – American College of Cardiology
Among persons with chronic kidney disease (CKD) and type 2 diabetes (T2D), combination therapy with finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio (UACR) than either drug alone, according to results from the CONFIDENCE trial published June 5 in the New England Journal of Medicine. In this double-blind multicenter trial, Rajiv Agarwal, MD, FACC, et al., randomized 800 patients (mean age 66 years, 25% women) to receive 10 or 20 mg of finerenon e once
